Discontinuing development of istisociclib, a CDK9 inhibitor; benefit-risk profile in platinum-resistant high-grade serous ...

Our novel scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss. By targeting C1q, our immunotherapies ...

Cantor analysts said they found the bone mineral density changes when reviewing supplemental data that was published along ...

What are your upcoming plans with respect to disease portfolio, partnerships, and molecule discovery and manufacturing in FY25 and upcoming financial year? LMS plans to expand its therapeutic ...